A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

NCT04153565 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma

Interventions

DRUG: Pembrolizumab
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

Merck Sharp & Dohme LLC